Mechanism of action of axitinib/axitinib

Axitinib/Axitinib is a small molecule tyrosine kinase inhibitor mainly used to treat renal cell carcinoma and some other solid tumors. Its mechanism of action is mainly by inhibiting a variety of tyrosine kinases related to tumor growth and metastasis, thereby intervening in the proliferation and angiogenesis of tumor cells.

Axitinib targets and inhibits the vascular endothelial growth factor receptor (VEGFR), which is one of the core mechanisms of its anti-tumor effect. VEGF is an important factor in promoting the formation of new blood vessels. In order to meet the needs of rapid growth, tumor cells will secrete a large amount of VEGF to promote angiogenesis and ensure adequate supply of oxygen and nutrients. Axitinib binds to and inhibits the activity of VEGFR, preventing the activation of this signaling pathway, thereby reducing the blood supply of tumors and limiting tumor growth.

In addition to inhibitingVEGFR, axitinib can also affect several other related tyrosine kinases, including smooth muscle growth factor receptor (PDGFR) and fibroblast growth factor receptor (FGFR). These receptors play important roles in tumor growth, metastasis and remodeling of the microenvironment. By inhibiting multiple signaling pathways at the same time, axitinib can more comprehensively intervene in the biological behavior of tumors and improve the therapeutic effect.

Clinical studies have shown that axitinib can significantly prolong progression-free survival in patients with advanced renal cell carcinoma. This makes it one of the important options in first- or second-line treatment options. Patients generally experience improved disease control with axitinib, although they need to be wary of possible side effects such as hypertension, fatigue, and oral ulcers.

In summary, axitinib exerts its anti-tumor effects by inhibiting multiple tyrosine kinases, especiallyVEGFR. The drug can effectively control tumor growth by inhibiting angiogenesis and signaling pathways required by tumors.

Reference materials:https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84137882-e000-47da-bd5b-fa76ab3c76f9##